{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:40:13Z","timestamp":1788478813628,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ebiom.2022.104298","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:58:47Z","timestamp":1665428327000},"page":"104298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"special_numbering":"C","title":["Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial"],"prefix":"10.1016","volume":"85","author":[{"given":"Meera","family":"Madhavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Aboagye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3088-310X","authenticated-orcid":false,"given":"Daniel","family":"Jenkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Provstgaad-Morys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Tarbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Flaxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Belij-Rammerstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deidre","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Villafana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-7562","authenticated-orcid":false,"given":"Alexander D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104298_bib0001","doi-asserted-by":"crossref","unstructured":"Ponce-de-Leon S, Torres M, Soto-Ramirez LE, et\u00a0al. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: interim results of a non-randomized open label phase I trial in Mexico. medRxiv. 2022.","DOI":"10.1101\/2022.02.08.22270676"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104298_bib0002","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2022.104298_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: from bench to bed","volume":"76","author":"Alu","year":"2022","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104298_bib0004","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104298_bib0005","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104298_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109055","article-title":"SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery","volume":"35","author":"Mulay","year":"2021","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104298_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/thoraxjnl-2021-217561","article-title":"Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19","volume":"77","author":"Bridges","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.ebiom.2022.104298_bib0008","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fimmu.2013.00222","article-title":"secretory IgA: designed for anti-microbial defense","volume":"4","author":"Brandtzaeg","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.104298_bib0009","article-title":"Tissue resident memory T cells in the respiratory tract","author":"Zheng","year":"2021","journal-title":"Mucosal Immunology"},{"issue":"577","key":"10.1016\/j.ebiom.2022.104298_bib0010","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"issue":"577","key":"10.1016\/j.ebiom.2022.104298_bib0011","doi-asserted-by":"crossref","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104298_bib0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(90)90250-P","article-title":"Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza","volume":"8","author":"Tamura","year":"1990","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.ebiom.2022.104298_bib0013","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104298_bib0014","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","article-title":"Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract","volume":"173","author":"Renegar","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104298_bib0015","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.4049\/jimmunol.168.6.2930","article-title":"Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines","volume":"168","author":"Asahi","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104298_bib0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CVI.00590-15","article-title":"Mucosal IgG levels correlate better with respiratory syncytial virus load and inflammation than plasma IgG levels","volume":"23","author":"Vissers","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104298_bib0017","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1128\/AAC.38.12.2785","article-title":"Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice","volume":"38","author":"Weltzin","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104298_bib0018","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1128\/jvi.61.6.1851-1854.1987","article-title":"Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats","volume":"61","author":"Prince","year":"1987","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104298_bib0019","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/infdis\/jiv281","article-title":"Effect of preexisting serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults","volume":"212","author":"Bagga","year":"2015","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104298_bib0020","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/vaccines9090998","article-title":"Safety and efficacy of spray intranasal live attenuated influenza vaccine: systematic review and meta-analysis","volume":"9","author":"Perego","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"9-10","key":"10.1016\/j.ebiom.2022.104298_bib0021","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0264-410X(01)00471-6","article-title":"Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis","volume":"20","author":"Beyer","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.104298_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103788","article-title":"Mucosal immune response in BNT162b2 COVID-19 vaccine recipients","volume":"75","author":"Azzi","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104298_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744887","article-title":"The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines","volume":"12","author":"Chan","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104298_bib0024","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-022-32389-8","article-title":"SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104298_bib0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"607","key":"10.1016\/j.ebiom.2022.104298_bib0026","doi-asserted-by":"crossref","first-page":"eabh0755","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"van Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104298_bib0027","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104298_bib0028","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ebiom.2022.104298_bib0029","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.vaccine.2004.07.043","article-title":"Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans","volume":"23","author":"Van Kampen","year":"2005","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104298_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008748","volume":"5","author":"Green","year":"2015","journal-title":"BMJ Open"},{"issue":"10249","key":"10.1016\/j.ebiom.2022.104298_bib0031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"7830","key":"10.1016\/j.ebiom.2022.104298_bib0032","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"10269","key":"10.1016\/j.ebiom.2022.104298_bib0033","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ebiom.2022.104298_bib0034","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104298_bib0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs","volume":"119","author":"Joe","year":"2021","journal-title":"Biotechnol Bioeng"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104298_bib0036","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ebiom.2022.104298_bib0037","unstructured":"Medicine and Healthcare products Regulatory Agency. Public Assessment Report, National procedure: Vaxzevria (previously COVID-19 Vaccine AstraZeneca, suspension for injection) COVID-19 Vaccine (ChAdOx1-S [recombinant]) PLGB 17901\/0355 2021 [Availablefrom:https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1003840\/CMA_UKPAR_COVID_19_Vaccine_AstraZeneca_PAR_16.07.2021.pdf. Accessed 22 February 2022"},{"issue":"22","key":"10.1016\/j.ebiom.2022.104298_bib0038","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"New Eng J Med"},{"issue":"e56413","key":"10.1016\/j.ebiom.2022.104298_bib0039","first-page":"1","article-title":"Absorption of nasal and bronchial fluids: precision sampling of the human respiratory mucosa and laboratory processing of samples","volume":"131","author":"Thwaites","year":"2018","journal-title":"J Visualized Experiment"},{"issue":"10267","key":"10.1016\/j.ebiom.2022.104298_bib0040","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104298_bib0041","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104298_bib0042","doi-asserted-by":"crossref","first-page":"16756","DOI":"10.1038\/srep16756","article-title":"Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice","volume":"5","author":"Dicks","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.104298_bib0043","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2015.02.050","article-title":"Mucosal vaccination by adenoviruses displaying reovirus sigma 1","volume":"482","author":"Weaver","year":"2015","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104298_bib0044","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104298_bib0045","doi-asserted-by":"crossref","first-page":"e155655","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2022.104298_bib0046","article-title":"Differential biodistribution of adenoviral-vectored vaccine following intranasal and endotracheal deliveries leads to different immune outcomes","volume":"13","author":"Jeyananthan","year":"2022","journal-title":"Front Immunol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:19:57Z","timestamp":1762456797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422004807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":46,"alternative-id":["S2352396422004807"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104298","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104298"}}